Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis - Wikidata - thesis-toulmin - TriplyDB

Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis

Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis

http://www.wikidata.org/entity/Q24685784

about

Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease The antibody targeting the E314 peptide of human Kv1.3 pore region serves as a novel, potent and specific channel blocker Recombinant expression of margatoxin and agitoxin-2 in Pichia pastoris: an efficient method for production of KV1.3 channel blockers Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion.Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis.Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis Potent suppression of Kv1.3 potassium channel and IL-2 secretion by diphenyl phosphine oxide-1 in human T cells.The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy.Factors influencing adverse skin responses in rats receiving repeated subcutaneous injections and potential impact on neurobehavior Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.Th17 cells in human disease.Use of Kv1.3 blockers for inflammatory skin conditions.Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis.Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques Ion channels in innate and adaptive immunity Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat.K+ channel modulators for the treatment of neurological disorders and autoimmune diseases Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy.Voltage-gated potassium channels as therapeutic targets.Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.Ion channels and anti-cancer immunity.The functional network of ion channels in T lymphocytes Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions.Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies.Novel Kv1.3 blockers for immunosuppression: WO2012155199.Dysregulated ΔNp63α negatively regulates the maspin promoter in keratinocytes via blocking endogenous p73 binding.The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies.Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate.Role of the K(Ca)3.1 K+ channel in auricular lymph node CD4+ T-lymphocyte function of the delayed-type hypersensitivity model.

P2860

Q24646861-A1FE4445-044E-43EC-8FC9-34CF022E9C56 Q24657847-24360B64-8785-44A6-ABED-6794171936AB Q27684056-A0485971-49F5-4C54-8450-703BDAF8B88C Q28280077-8A7B06DF-08B8-429D-9C5B-C9EB1A3F9EF3 Q28482737-BA99D110-2CD9-49DE-B031-AC8091456CE0 Q28484559-DE3A73D8-7A28-4300-A4F6-556EBAB8DAD5 Q30497371-EA30931A-CC90-4D12-94AF-B85D5A0D768F Q34277605-C2C2C9DA-7863-48B9-AF1F-2E9DC1CDB76D Q34343254-8BD5E955-EE3B-4F4E-91E5-B46CDAFFA3D2 Q34426259-F1DA3944-F456-4BAC-AE7A-C77FC498D8BF Q34437894-7BD1AAB9-4D8F-4AB3-B43B-E9FFE5DDC8B4 Q34746164-FE2FAC52-5548-4951-BD82-12E1A5B13181 Q35060404-62A9DEE8-5BC5-41F0-8C16-EB4A7D423C04 Q35100462-40B56193-AA66-40A3-809C-F86E8CB7C1D9 Q35429501-8363B746-E750-4D5C-8AE0-8F90F972A499 Q35660234-0FA1E9F5-9E95-4A5E-A919-FAD9007DD33B Q35820734-269D89A4-F1C0-4866-9FAB-CB3B9793E589 Q35915882-A726DA76-DF0C-4D3C-A375-7269434CB824 Q36016618-BC2DD041-EF96-4FF8-92A8-BAA7F91D3A29 Q36097325-C9B90351-D9E8-4B6B-9761-3B0C9506604C Q36099602-A30939F3-F8FF-4E6E-94AF-E9421C9BAB1B Q36255490-46D0BB76-2A32-4837-8D57-EE1BEA3D7A42 Q36666549-4E06618A-7139-49C2-9D5A-01AD92C5D951 Q36769825-7F134893-0115-4963-8D36-8537E82BDBE8 Q36815921-00BC2F80-624F-48DF-A705-E1E44CC2171E Q37162392-5EA6D184-1D2E-4070-965E-66BD55BA8FE4 Q37346963-545C3146-3E0E-45D5-A1D8-CD2C7423004A Q37395286-D262A1E1-0FDE-4A89-B642-1E628E5FF0C1 Q37464784-1466143C-7BE7-4559-9B3F-ADC711921560 Q37523986-4B1EFA37-D32C-415C-92DD-31062A27A700 Q37566472-633039A3-9AD9-41D4-AA81-8FED21FC73CB Q37597609-97C6BCD6-8992-48DF-AB12-3F9EB87CDB27 Q37681821-DC38400F-F6AF-43BF-8200-657057A03A02 Q37720518-3353FF11-E832-4160-BE6E-99FB1F623620 Q38130764-97CD25D1-3D0F-4331-A2D5-780A595CE0AF Q38317198-7C172BFC-3B0D-4F02-9BCD-1D9AEA5022AF Q38658556-4F108155-A6FA-42EF-8E13-A5D39466B63F Q39906630-4B90216C-9B88-4AFF-858F-082FF5BFD666 Q41048502-E15FDD64-B544-41BC-8561-3A0E69B6357A Q41482329-A9AB1D94-ADE7-444D-9AE5-20FF9EE498A8

P2860

Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis

http://www.wikidata.org/entity/Q24685784

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Targeting effector memory T ce ...... es allergic contact dermatitis

@ast

Targeting effector memory T ce ...... es allergic contact dermatitis

@en

Targeting effector memory T ce ...... es allergic contact dermatitis

@nl

type

label

Targeting effector memory T ce ...... es allergic contact dermatitis

@ast

Targeting effector memory T ce ...... es allergic contact dermatitis

@en

Targeting effector memory T ce ...... es allergic contact dermatitis

@nl

prefLabel

Targeting effector memory T ce ...... es allergic contact dermatitis

@ast

Targeting effector memory T ce ...... es allergic contact dermatitis

@en

Targeting effector memory T ce ...... es allergic contact dermatitis

@nl

P1433

Q24685784-1C1074F2-A917-4BE9-A134-5A3B5A4F3D90

P1476

Q24685784-4E075762-1836-49A4-9FE1-4221A6CF86B8

P2093

Q24685784-7C92298A-475E-483C-9104-80ED1E0FEC69

Q24685784-98978D60-62A6-48B5-94B0-B0F5EB560C88

Q24685784-BA30C18D-7522-47B3-AC37-27F816EB2060

Q24685784-BCEBDCE5-42A9-403F-843F-DF993949C7A4

Q24685784-C51C789F-FFED-4496-B236-56301D0C3E66

P2860

Q24685784-084A9C1A-FD8E-4EE8-859B-5AB68C5F8D76

Q24685784-0A5B932F-8D1D-4665-8C6D-432E43ACF20A

Q24685784-0C98E6D3-213C-4529-AFF1-0A5D3FB51522

Q24685784-0D6F53FC-BDE0-4039-9BC4-E58E8330001E

Q24685784-0F8F0CDC-978A-4070-A7F4-B540C42D837A

Q24685784-13ADA7FF-A81A-451C-A726-B645AB0DC6F2

Q24685784-165B773A-A1C4-465E-9B33-AED40D622D25

Q24685784-1B820B72-E8B9-4135-9955-3283AE90EDB5

Q24685784-1DC797E6-4EF0-4405-9FB5-0F815BA44244

Q24685784-21C7BDF5-62FE-44B1-B171-62C2E59003F7

P2888

Q24685784-52B611D2-4BB6-4A8A-A43D-F7BBFBA65200

P304

Q24685784-61BCF47D-F42D-4F22-A1FA-E6DF949F1E17

P31

Q24685784-96B2A985-1956-4900-8D99-E2A5DAB85682

P3181

Q24685784-286D94D1-7B02-42FA-A420-D15FC71F5882

P356

Q24685784-7E667B92-6675-47AA-B9EC-890583215265

P407

Q24685784-0FBE1CC0-B334-469F-9F3B-A66258FDA591

P433

Q24685784-EC11B826-6FCB-48A2-B1AB-841A434C7D25

P478

Q24685784-CAE05FA9-D78A-4D45-B95C-4A2A65805CD2

P577

Q24685784-03517DAB-8A4D-4AFF-BCDF-06A0AA22A383

P5875

Q24685784-C3A0FE29-D726-4D15-AE76-223B47D679D9

P6179

Q24685784-BF8AE343-02E2-44B7-B307-08D5F3EFED9F

P698

Q24685784-3C8E5EB9-B7F2-4BDE-AFA4-EB3AAB477BA9

P921

Q24685784-5B5D115E-9E5B-48EE-9185-57B88FB34647

P932

Q24685784-5E64C445-3E60-4417-9880-54C10705558D

P3181

P356

P1433

Journal of Investigative Dermatology

P1476

Targeting effector memory T ce ...... es allergic contact dermatitis

@en

P2093

Ananthakrishnan Sankaranarayanan

http://www.w3.org/2001/XMLSchema#string

Daniel Homerick

http://www.w3.org/2001/XMLSchema#string

Heike Wulff

http://www.w3.org/2001/XMLSchema#string

Philippe Azam

http://www.w3.org/2001/XMLSchema#string

Stephen Griffey

http://www.w3.org/2001/XMLSchema#string

P2860

Human IL-17: a novel cytokine derived from T cells

A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes

The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain

Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis

K+ channels as targets for specific immunomodulation

CD4+CD28- costimulation-independent T cells in multiple sclerosis

The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS

HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation

Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

P2888

P304

1419-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3175112

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.JID.5700717

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6531795

http://www.w3.org/2001/XMLSchema#string

P6179

1042752121

http://www.w3.org/2001/XMLSchema#string

P698

17273162

http://www.w3.org/2001/XMLSchema#string

P921

P932

1929164

http://www.w3.org/2001/XMLSchema#string